Australia's most trusted
source of pharma news
Posted 21 April 2026 PM
Specialised Therapeutics (ST) has secured a broader label for lung cancer drug Zepzelca in Australia and Singapore, though the new indication has already been knocked back by the PBAC.
In combination with Roche’s Tecentriq, Zepzelca has been approved by the TGA and Singapore’s Health Sciences Authority as a maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC) in adults whose disease has not progressed after first-line induction therapy with Tecentriq, carboplatin and etoposide.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.